Phathom Pharmaceuticals, Inc. (PHAT) Cash Flow Statement

The persistent gap between net income and operating cash flow indicates that the company is currently in a phase where accounting losses are exacerbated by the cash-intensive nature of its commercial launch. Investors should monitor whether the OCF/NI ratio stabilizes as the company moves toward a more mature revenue base, as current figures suggest a heavy reliance on external financing to bridge the operational deficit.

The trajectory of free cash flow appears to be improving from the extreme outflows seen in 2025, yet the absolute level of burn remains a critical concern for long-term solvency. This trend suggests that while the company is scaling, the path to positive free cash flow is contingent upon achieving significant prescription volume growth to offset the high fixed costs of its commercial infrastructure.

The low capital intensity suggests that the company is effectively leveraging an asset-light model for its core operations, focusing its resources on sales and marketing rather than capital-heavy production. This structure implies that any future improvement in cash flow will be driven by operating leverage rather than a reduction in capital spending.

The volatility in working capital appears to be a byproduct of the transition from clinical-stage to commercial-stage operations, where inventory and receivables management are still finding a steady state. Investors should monitor these fluctuations closely, as they may obscure the true underlying cash burn rate during the early phases of market penetration.